Journal of Psychopharmacology · 2004 · 94 citations · 156 references
MedicinePharmacologyPsychiatryNeuropharmacologyNeuropsychiatryPsychopharmacologyAddictionCognitive ImpairmentNeurotransmissionNicotine AddictionNicotine PharmacologyTobacco UseCognitive PerformanceCognitive Performance ImpairmentCognitive Performance TestingNeuropsychiatric EffectsNicotine Receptor PharmacologyNicotinic Acetylcholine Receptor AgonismNicotinic Receptor PharmacologyTobacco Addiction
Cigarette smoking rates in the American population are approximately 23%, whereas rates of smoking in clinical and population studies of individuals with neuropsychiatric disorders are typically two- to four-fold higher. Studies conducted in a variety of neuropsychiatric populations [e.g. attention-deficit hyperactivity disorder (ADHD), Alzheimer's disease, schizophrenia] have collectively suggested that nicotine may be efficacious in remediating selected cognitive deficits associated with these disorders, thus providing a framework for understanding the specific vulnerability of these patients to smoking initiation and maintenance. However, the specific gain in cognitive performance produced by nicotine administration in healthy subjects with normal cognitive function is less clear. This article reviews our current understanding of central nicotinic acetylcholine receptor (nAChRs) systems in normal and neuropsychiatric disease states and, specifically, their role with respect to cognitive dysfunction and clinical symptoms in several specific neuropsychiatric populations, including ADHD, Alzheimer's disease, Parkinson's disease, Tourette's Disorder, schizophrenia and affective disorders. The potential benefits of nicotinic agents for therapeutic use in neuropsychiatric disorders is discussed, as well as directions for further research in this area.
156
Karen E. Lasser, J. Wesley Boyd, Steffie Woolhandler et al. · JAMA · 2000 · 2.5K citations
Kenneth S. Kendler · Archives of General Psychiatry · 1993 · 811 citations